Aphria’s (TSX:APH) Share Price Is Still Too High for a Buy
The Motley Fool
Published Nov 12, 2018 12:57
Updated Nov 12, 2018 13:15
Which Canadian cannabis stocks to buy and hold for the long term has been almost the primary concern of investment pundits across the country these last six months or so. Investing tips for beginners have been riddled with outlandish promises of this huge growth industry.
So far, however, legal marijuana has been a big letdown post October 17. That said, the following stock is standing its ground, likely due to its position in pharma-grade marijuana. Let’s see if the data says it’s a buy.
Aphria (TSX:APHA)(NYSE:APHA)
Scour any list of TSX cannabis stocks to watch today and you’ll see this NYSE-listed ticker somewhere near the top. Canadian stocks in the mid-to-large cap range rarely come as volatile as this $4 billion pot asset, though with a PEG of 1.8 times growth and debt 3.8% of net worth a canny investor might begin to see why it might be a front runner of legal marijuana.
There is some very encouraging data out there for this stock, despite its current share price, such as a one-year past earnings growth of 94% and a five-year average past earnings growth of 89.6%. This is great to see for a player in so young an industry, and bodes well for Aphria, which could become one of the best pot stocks to buy right now. But is Aphria stock a buy, or should new positions be minimized ahead of another downturn in the fledgling legal recreational pot industry?
Value, quality, or momentum: where does Aphria excel?
Two overheated market variables and a missing key shareholder return mean that Aphria’s main strength is not going to be value. To put a finer point on it, a P/E of 89 times earnings, P/B of 2.8 times book, and lack of dividends mean that this stock has poor value at $15.15 a share.
Aphria stock scores a little better on quality, though it should be pointed out that a ROE of 2% and most recent EPS of $0.19 do not indicate a classy stock, leaving a 50.6% expected annual growth in earnings to put in overtime in the “hot shot stock” department.
When we come to momentum, we start to get an idea of where Aphria’s main utility lies. Aphria’s share price shed 6.6% in the last five days, while a 36-month beta of 3.46 indicates high volatility, and its share price is overvalued by over 3.5 times its future cash flow value.
Get The App
While upward momentum may well be more useful for those investors unused to trading on the price difference of a stock, an opportunity may exist here for the capital gains investor still bullish on weed .
The bottom line
If you want to make money with cannabis stocks, momentum and upside are your key investment strategies. While much of the capital gains to be had in the legal weed industry may have materialized already – at least for the time being – Aphria stock might be emblematic of the way forward if you want to invest in Canadian marijuana.
For the general investor, though, poor value and mixed quality might not make up for what is essentially a stock for momentum-focused traders only, with an overall sell signal.
Fool contributor Victoria Hetherington has no position in any of the stocks mentioned.
This Article Was First Published on The Motley Fool
Written By: The Motley Fool
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.